Korea/Asia, Events, IPOs, Douglas Research Advisory

Douglas Kim

Nearly 30 years of experience in the Korean/Asian equity research. Major sectors coverage include the following:
- Technology 
- Consumer 
- Special Situations/Deep Value Plays
- Tender Offers/M&As
- Holdcos/Stubs
- Asian Unicorns/Private Companies

Korea/Asia, Events, IPOs

Uni-President China - Strong margin expansion in 1Q24

Douglas Research Advisory

Equity Bottom-Up

<ul>
<li>Grape King Bio has one of the most remarkable consistency in profit margins among all Asian F&amp;B companies. Its net margins ranged from 13% to 15% in the past decade.</li>
<li>The company's dividend yield increased from 3.8% in 2021 to 4.1% in 2022, and 4.4% in 2023. Its annual dividend payout averaged 69.6% from 2019 to 2023. </li>
<li>Established in 1969, Grape King Bio is one of the leading health food, drink, and supplement products manufacturers in Taiwan.</li>
</ul>


Grape King Bio has one of the most remarkable consistency in profit margins among all Asian F&amp;B companies. Its net margins ranged from 13% to 15% in the past decade.
The company's dividend yield increased from 3.8% in 2021 to 4.1% in 2022, and 4.4% in 2023. Its annual dividend payout averaged 69.6% from 2019 to 2023. 
Established in 1969, Grape King Bio is one of the leading health food, drink, and supplement products manufacturers in Taiwan.


Grape King Bio

Asian Dividend Gems: Grape King Bio